v3.26.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Information [Abstract]  
Schedule of Consolidated Net Loss

The following table reflects segment profit or loss, significant expense categories and other segment items regularly provided to the CODM when managing the Company’s reportable segments. A reconciliation to the consolidated net loss for the periods ended March 31, 2026 and 2025 is included at the bottom of the table below.

 

   For the Three Months Ended
March 31, 2026		       For the Three Months Ended
March 31, 2025		 
   Biotech   Mining   Total   Biotech   Total 
Significant segment expenses                    
General and administrative  $6,088,082   $124,247        6,212,329    850,282    850,282 
Research and development   321,271    
-
    321,271    
-
    
-
 
Professional fees   2,770,181    208,508    2,978,689    736,686    736,686 
Interest expense   1,615    
-
    1,615    553,937    553,937 
Impairment expense   2,045,253    
-
    2,045,253    
-
    
-
 
Other segment items   (16,307)   
-
    (16,307)   (10,664)   (10,664)
Total operating and segment expenses  $11,210,095   $332,755    11,542,850    2,130,241    2,130,241 
                          
Reconciliation of net loss                         
Change in fair value of warrant liabilities             2,314,353         (13,515)
Consolidated net loss             13,857,203         2,116,726